Sustained growth despite negative currency effect

11/06/2013

2013 nine-month sales
 (1 January to 30 September 2013) 

 

Sales up 10.9% at constant exchange rates

Growth in all geographic regions and markets

 Increasing contributions from emerging countries

 

Press release

 

Avignon, 5 November 2013 - Naturex, the global leader in speciality plant-based natural ingredients, announces its consolidated revenue for the first nine months of fiscal 2013:

€000s

IFRS

FY 2013 FY 2012 Change (%) Change (%)
 at constant exchange rates 
1st quarter 83,196 73,473 +13.2% +14.4%
2nd quarter 82,558 73,684 +12.0% +12.5%
3rd quarter 76,817 75,973 +1.1% +6.0%
9-month revenue (YTD) 242,571 223,130 +8.7% +10.9%

 

Consolidated revenue for the first nine months of 2013 came to €242.6 million, up 8.7% from last year's same period.

At constant exchange rates, sales rose 10.9% with 8.6% in organic growth and 2.3% from changes in Group structure (business of Decas Botanical Synergies consolidated on 19 September 2012).

Foreign exchange trends had a negative impact in the period, particularly in the 2013 third quarter, reflecting the depreciation of several currencies versus the euro including the US and Australian dollars and selected emerging country currencies (Brazil, Mexico, China, Russia, India, etc.).

On that basis, third-quarter sales at constant exchange rates rose 6% in relation to particularly strong sales in the same quarter in 2012.

 

Good performances in three markets

€000s

IFRS

9 months
 FY 2013
9 months
 FY 2012

Change

(%)

Revenue mix

(%)

Change (%)
 at constant exchange rates
Food & Beverage 141,552 142,783 -0.9% 58.4% +1.6%
Nutrition & Health 83,489 66,535 +25.5% 34.4% +27.3%
Personal Care 4,291 3,621 +18.5% 1.8% +21.6%
Toll-Manufacturing and misc. 13,239 10,191 +29.9% 5.5% +30.1%

 

 

Good resilience in mature markets and positive momentum in emerging countries

€000s

IFRS

9 months
 FY 2013
9 months
 FY 2012*

Change

(%)

Revenue mix

(%)

Change (%)
 at constant exchange rates
 
Europe/Africa 113,891 106,370 +7.1% 47.0% +7.9%
Americas 98,484 89,306 +10.3% 40.6% +13.3%
Asia/Pacific 30,196 27,454 +10.0% 12.4% +14.6%
               

* To take into account the geographic breakdown of our Sales Divisions, countries of the Middle East region previously included in Europe/Africa are henceforth presented within the Asia/Pacific region. The revenue breakdown by geographic region for the first nine months of 2012 in consequence takes into account this new presentation.

 

All geographic regions delivered good growth, both in mature markets still affected by a difficult economic environment in Europe, and emerging markets with continuing momentum that accounted for 17.9% of Group sales for the 2013 nine-month period and 21.1% for the 2013 third-quarter.  

 

"Since the year's start we have achieved excellent gains for sales in each region where we operate, despite uncertainties linked to the global economic environment, commented Naturex's Chairman-CEO, Thierry Lambert. “In line with expectations, due to adverse effects of trends for certain currencies and a less favourable comparison base, the pace of expansion in the 2013 third quarter was slightly less sustained than in the first half. With growth prospects driven by our focus on scientific innovation and the dynamism of our sales network, combined with a selective acquisition strategy, we can look to the future with confidence."

 

You can receive all financial information of Naturex free of charge by signing up at: www.naturex.com 

Financial schedule

-          Q3 2013 results 29 November 2013

Upcoming events

-          The Actionaria Trade Show 22 and 23 November 2013

 

 

 

Naturex has been listed since October 1996 on NYSE Euronext in Paris, Segment B

 

Total number of shares comprising the share capital: 7 842 215

ISIN FR0000054694

 

Naturex is a component of the CAC Small and Gaïa indexes.

Naturex is eligible for the "long only" Deferred Settlement Service (SRD).

Naturex established a Sponsored Level 1 American Depositary Receipt (ADR) program in the United States. Under this facility, Naturex’s ADRs are traded over-the-counter in the United States under the symbol NTUXY.

 

SYMBOL: NRX - Reuters: NATU.PA - Bloomberg: NRX: FP - DR Symbol: NTUXY

 

About Naturex

Naturex is the global leader in speciality plant-based natural ingredients. The Group is organised around three strategic markets (food & beverage, nutrition & health and personal care) and produces and markets speciality plant-based ingredients for the food, nutraceutical, pharmaceutical and cosmetic industries.

 

Naturex’s head office is based in Avignon. The company employs more than 1,400 people with 8 sourcing offices located throughout the world and high-performance manufacturing operations across 15 sites in Europe, Morocco, the United States, Brazil, Australia and India. It also has a global commercial presence through a dedicated network of sales offices in more than 20 countries.        

 

 

 Contacts  

 

Thierry Lambert

Chairman and Chief Executive Officer

Tel.: +33 (0)4 90 23 96 89

t.lambert@naturex.com

 

 

 

 

Thierry Bertrand Lambert

Chief Financial Officer

Tel.: +33 (0)4 90 23 96 89

t.b.lambert@naturex.com

 

Carole Alexandre

Investor Relations

Tel.: +33 (0)4 90 23 78 28

c.alexandre@naturex.com

Anne Catherine Bonjour

Actus Finance Press Relations

Tel.: +33 (0)1 53 67 36 93

acbonjour@actus.fr

 

 

 

actu_169_Fichierpdf.pdf
 
of 221
BACK